Astellas’s $50 Million Investment to Support Poseida’s Commitment to Redefining Cancer Cell Therapy

Cooley LLP advised Poseida Therapeutics on the deal.Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) and Poseida Therapeutics, Inc. (NASDAQ: PSTX, CEO: Mark…

This content is for Standard 1 Year members only.
Login Join Now
Laura Testa

Author: Laura Testa

This content is for Standard 1 Year members only.
Login Join Now